HCPLive

05/12/2026

New consensus definitions for low disease activity and remission in atopic dermatitis may help standardize how clinicians, researchers, and regulators evaluate treatment success.

In an HCPLive interview, Raj Chovatiya, MD, PhD, of Rosalind Franklin University Chicago Medical School, discusses why combining clinician-reported signs with patient-reported symptoms is essential for accurately assessing disease control in eczema.

The conversation also explores how these definitions could improve clinical trial design, regulatory clarity, and future treat-to-target strategies in atopic dermatitis.

Read more:
https://hubs.li/Q04g9hv60

05/12/2026

Food allergy management is evolving beyond strict avoidance toward more individualized care strategies tailored to patient goals, risk profiles, and quality of life.
In recognition of , Christopher Brooks, MD, of The Ohio State University discusses the growing role of food challenges, omalizumab, oral immunotherapy, and ongoing gaps in diagnosis and treatment education across specialties.
Brooks also highlights why confirming true food allergy remains critical before patients undergo restrictive diets or time-intensive therapies.

https://hubs.li/Q04g9HTw0

05/11/2026

For patients with growth hormone deficiency, the conversation shouldn’t end at adult height.

In this latest peer exchange from HCPLive, expert endocrinologists discuss why early patient education is essential during the transition from pediatric to adult care—helping patients understand growth hormone’s ongoing role in bone health, lean muscle mass, and long-term metabolic outcomes.

How are you approaching transition-of-care conversations with patients and families?

Watch now: https://hubs.li/Q04g54_40

Featuring: Craig Alter, MD ; Nidhi Agrawal, MD ; Joshua Yang, MD ; Jose Garcia, MD, PhD

05/10/2026

This National Day, we spoke with Joseph Saseen, MD, from the University of Colorado Anschutz, to catch up on recent developments in dyslipidemia management - and where we still have to go to bring this cardiovascular risk factor into check.

Watch now: https://hubs.li/Q04g068q0

05/10/2026

New data show that expansion then later reduction of allergen-specific type 2 memory B cells is tied to sustained symptom improvement in & . Read Q&A with Menno C. van Zelm, PhD, here:

In 38 patients with house dust mite allergy, 18 months of SLIT was linked to early expansion and later reduction of allergen-specific type 2 memory B cells.

05/09/2026

is set for major late-breaking respiratory data. biologics, immunomodulators, and MAC lung disease regimens headline this year’s meeting in Orlando. Full preview of expert interviews + key trial readouts: https://hubs.li/Q04g0kfV0

05/09/2026

New data from the ACACIA-HCM trial have shown aficamten's noninferiority to placebo in treating nonobstructive hypertrophic cardiomyopathy. We met with Ahmad Masri, MD, of Oregon Health & Science University, to learn more.

Watch now: https://hubs.li/Q04g0fKn0

05/08/2026

Could mitochondrial uncoupling offer a new path forward in treatment? Mazen Noureddin, MD, discusses HU6’s liver-centric effects, visceral fat reduction, and muscle-preserving weight loss in phase 2 AMPLIFY: https://hubs.li/Q04g04F20

05/08/2026

Hypertension is one of the most common cardiovascular conditions in the world - so why aren't we managing it better? With the help of Viet Le, DMSc, PA-C, of Intermountain Health, and Deepak Bhatt, MD, MPH, of Mount Sinai Fuster Heart Hospital, we dive into this paradox and explore the ways in which clinicians can help educate their patients about the risks, identification, and management of a leading cause of cardiovascular mortality.

Read more: https://hubs.li/Q04fVZZ00

05/08/2026

Watch experts Dr. April Armstrong, MD, MPH and Dr. Tina Bhutani-Jacques, MD, MAS, FAAD as they compare deucravacitinib and apremilast. They’ll break down efficacy, safety, and patient centered outcomes.

Watch the full discussion: https://hubs.li/Q03ZnjCM0

05/08/2026

Routine mental health screening in IBD clinics was linked to significantly greater psychogastroenterology referral and follow-up rates at , highlighting the growing role of integrated behavioral care in GI practice. https://hubs.li/Q04fVZfP0